RC WILD BIOPHARMA CONSULTING, LLC
RC Wild BioPharma Consulting, LLC is a boutique biotech & pharmaceutical consulting firm. We provide high quality strategy consulting services to clients in pharma, biotech, venture capital and other investment firms with a specific focus on oncology drug discovery and development.
Robert Wild, Ph.D. (President and Founder of RC Wild BioPharma Consulting, LLC)
Dr. Wild is a visionary and strategic R&D executive with more than two decades of broad leadership experience in the pharmaceutical/biotech & venture capital industry including 13 years experience at the C-level across large pharma, mid-size public biotech and private entrepreneurial settings. He has deep knowledge of the oncology drug discovery & development process spanning both small molecules and biologics. Throughout his career, Dr. Wild contributed to the discovery and translational research of more than 20 highly innovative oncology clinical development candidates including 5 FDA approved agents (sunitinib, cetuximab, dasatinib, erlotinib and entrectinib). He has extensive track record in technology/asset identification & assessment, discovery and translational research, project & portfolio management as well as corporate strategy including fund raising and supporting M&A activities for both private and public companies. As an EIR in the venture capital field for the past 7 years, Dr. Wild has consulted on identifying investment opportunities, conducting due diligence of target companies, helping to manage portfolio companies, and performing a variety of other duties.
Previously, Dr. Wild was the Chief Scientific Officer and Co-Founder of Dracen Pharmaceuticals, Inc., a private biotechnology company developing novel oncology drugs in the field of immuno-metabolism. As one of the founding executives of the company, Dr. Wild played an instrumental role in getting the company established including the drafting of the initial business plan, securing the lead asset and associated licenses, successfully raising a Series A and follow-on private equity financing ($57M+) and building an integrated drug discovery and development organization with internal hires, external consultants and CROs. As Chief Scientific Officer, his responsibilities included setting and executing the overarching R&D strategy and managing all drug discovery (biology and chemistry), preclinical development, CMC and translational research (patient selection and PD biomarker strategy) activities leading to the identification/selection and development of Dracen’s first clinical drug candidate (sirpiglenastat). Sirpiglenastat successfully completed phase 1 clinical development and received fast track designation (FTD) by the FDA. Before Dracen, Dr. Wild was employed at Ignyta, Inc. (NASDAQ: RXDX, acquired by Roche) where he functioned as the Chief Scientific Officer and Senior Vice President of Research. At Ignyta, he was responsible for setting overarching research strategy and leading all drug discovery as well as translational research activities within the company. Dr. Wild played a crucial role in building Ignyta’s research organization and capabilities. In addition, he helped transform Ignyta from a single asset company to a diversified company with multiple clinical stage programs via strategic asset identification and successful acquisition of 5 differentiated NMEs from pharma partners. During his tenure, the companies' lead asset (entrectinib) successfully advanced from phase 1 into a registration enabling phase 2 clinical trial leading to eventual FDA approval. Before Ignyta, Dr. Wild worked at Eli Lilly & Company (NASDAQ: LLY) as the Chief Scientific Officer, Oncology Research. In this role, he broadly oversaw oncology drug discovery activities from target discovery to clinical candidate selection for both small molecule and biotherapeutic approaches at the Lilly Corporate Center in Indianapolis. Under his leadership, his teams successfully advanced 5 IND candidates (3 small molecules, 2 biologics), >15 programs progressed to full discovery, and >40 programs advanced to early discovery. His teams also effectively supported >10 programs during various stages of clinical development (phase 1-3) with biomarker and translational research expertise. Dr. Wild also directed Lilly’s Oncology Research initiatives in Asia. Prior to Lilly, Dr. Wild held positions of increasing responsibility at OSI Pharmaceuticals, Inc. (NASDAQ: OSIP, acquired by Astellas Pharma), including Senior Director, Oncology Research. At OSI, Dr. Wild contributed to the delivery of 4 oncology IND candidates to clinical development, with continued responsibility for guiding translational research teams for these clinical development programs, including erlotinib. Before his tenure at OSI, Dr. Wild spent close to five years at Bristol-Myers Squibb, where he contributed to multiple oncology project teams, including those discovering dasatinib and the translational research team supporting cetuximab clinical development. Dr. Wild started his pharma/biotech career at SUGEN, Inc. (acquired by Pfizer, Inc.) where he was a member of the sunitinib discovery and translational research team.
Dr. Wild is a dual citizen of the US and Germany and currently resides with his family in Southern California. He holds both a Ph.D. degree in Pharmacology and a B.S. degree in biochemistry, magna cum laude, from the University of Minnesota, Minneapolis.
Discovering and developing a new medicine requires more than a great drug candidate. In todays market place, one not only needs to have a very deep understanding of the science underlying the invention but also requires a precise positioning of the asset in the context of the competitive environment including the clinical need as well as the regulatory landscape.
RC Wild BioPharma Consulting helps companies succeed and bring new drugs to patients in need for life saving medicines. RC Wild BioPharma Consulting builds on Dr. Wild’s extensive experience in various leadership roles within the biotech/pharmaceutical industry. We help our clients in the following key areas:
Asset/technology assessment including asset sourcing, diligence and competitive environment assessment
Early target identification/validation strategy and target/project prioritization
Drug discovery strategy and process optimization from screening through clinical candidate selection
Program management, general preclinical development and IND filing
Biomarker and companion diagnostics strategy
Clinical PoC, clinical development, translational research, as well as regulatory strategy
Corporate strategy including portfolio prioritization, fund raising and M&A activity
Please contact us to discuss how RC Wild BioPharma Consulting could assist you with your next corporate or R&D project and help guide your drug candidate through the finish line.